The US Food and Drug Administration (FDA) has granted breakthrough device designation to the Elecsys Neurofilament Light Chain (NfL) test for multiple sclerosis (MS). November, 2023
Made by Roche, the test is intended to be used as an aid in detection of disease activity in adults aged 18-55 years with relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS), providing insights for disease management.